Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Patients after kidney transplantation who develop donor-specific antibodies (DSA) are at high risk for antibody-mediated rejection (ABMR). Donor-derived cell-free DNA (dd-cfDNA) levels have been shown to be increased in patients with active or chronic active ABMR. This study aims to evaluate if repeated analysis of dd-cfDNA in patients with DSA and kidney allograft biopsy which is triggered by increased levels of dd-cfDNA can lead to early diagnosis of active or chronic active ABMR among these patients.
Epistemonikos ID: 37e11a68b90eb8bb1a6615cc36870ea275139514
First added on: May 08, 2024